Crewe Advisors’s Omega Healthcare OHI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$48 Buy
+1
New +$46 ﹤0.01% 1121
2026
Q1
Sell
-16
Closed -$710 1110
2025
Q4
$710 Buy
+16
New +$689 ﹤0.01% 1023
2025
Q2
Sell
-1,321
Closed -$50.3K 814
2025
Q1
$50.3K Hold
1,321
0.01% 270
2024
Q4
$50K Hold
1,321
0.01% 283
2024
Q3
$53.8K Hold
1,321
0.01% 294
2024
Q2
$45.2K Hold
1,321
0.01% 385
2024
Q1
$41.8K Hold
1,321
﹤0.01% 385
2023
Q4
$40.5K Hold
1,321
0.01% 136
2023
Q3
$43.8K Hold
1,321
0.01% 152
2023
Q2
$40.5K Hold
1,321
0.01% 291
2023
Q1
$36.2K Hold
1,321
0.01% 347
2022
Q4
$36.9K Hold
1,321
0.01% 339
2022
Q3
$39K Hold
1,321
0.01% 350
2022
Q2
$37K Hold
1,321
0.01% 331
2022
Q1
$41K Hold
1,321
0.01% 239
2021
Q4
$39K Hold
1,321
0.01% 211
2021
Q3
$40K Hold
1,321
0.01% 164
2021
Q2
$48K Hold
1,321
0.01% 157
2021
Q1
$48K Hold
1,321
0.01% 154
2020
Q4
$48K Buy
+1,321
New +$44.8K 0.02% 145

Other funds holding OHI

Crewe Advisors's OHI Position: Q2 2026 in Review

Crewe Advisors opened a new position in Omega Healthcare (OHI) in Q2 2026: 1 share worth $48. The stake represents ﹤0.01% of the portfolio and ranks #1121 among its holdings. This is a return to the name: Crewe Advisors previously reported a position in OHI as recently as Q4 2025.

Crewe Advisors first reported a position in OHI in Q4 2020 and has held it in 20 quarters since. The position peaked at $53.8K in Q3 2024. 762 funds tracked by Wall St. Rank hold OHI as of Q2 2026.

  • Crewe Advisors held 1 share of Omega Healthcare worth $48 as of Q2 2026.
  • Omega Healthcare was a new Crewe Advisors position in Q2 2026.
  • Omega Healthcare made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #1121 holding.
  • Crewe Advisors first reported a position in Omega Healthcare in Q4 2020 and has held it in 20 quarters since.
  • Crewe Advisors's Omega Healthcare position peaked at $53.8K in Q3 2024.
  • 762 funds tracked by Wall St. Rank held Omega Healthcare as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.